Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels—A pilot study - Eckl‐Dorna, J.; Fröschl, R.; Lupinek, C.; Kiss, R.; Gattinger, P.; Marth, K.; Campana, R.; Mittermann, I.; Blatt, K.; Valent, P.; Selb, R.; Mayer, A.; et al. (Allergy (Copenhagen), 2018)
Keywords: Administration, Intranasal; Adult; allergen; Allergens; Allergens - administration & dosage; Allergens - immunology; Allergies; Anti-Allergic Agents - administration & dosage; Antigens, Plant - administration & dosage; Antigens, Plant - immunology; Bet v 1 antigen; CD40 antigen; Double-Blind Method; Female; half‐life; Humans; IgE; Immunoglobulin E; Immunoglobulin E - analysis; Immunoglobulin E - immunology; Immunoglobulin G; Immunotherapy; Intranasal administration; intranasal challenge; Male; Monoclonal antibodies; Nose; omalizumab; Omalizumab - administration & dosage; Original; ORIGINAL ARTICLES; Patients; Pilot Projects; Pollen; Rhinitis, Allergic, Seasonal - immunology; Young Adult; allergen; omalizumab; intranasal challenge; half-life; IgE